

Davidson, Mark

From: Davidson, Mark
Sent: Friday, August 11, 2017 9:44 AM
To: 'Rizwana Sproule'
Cc: 'Alex Babayan'; 'Nadia Agopyan'
Subject: Kite Pharma Clinical IR 8.11.17

Importance: High

Dear Dr. Sproule,

“Please provide subjects IDs of all subjects that did not have CRS events in ZUMA-1 (Phase 1 and Phase 2)”

Provide response by COB Today 8/11/2017.

Mark L. Davidson, RHIA
Regulatory Project Manager
OTAT/CBER/FDA
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
Phone: 240-402-8277
Fax:301-595-1303
mark.davidson@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."